The ratings of five biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
SIGA Technologies, Inc. (SIGA) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). SIGA Technologies is a bio-defense company engaged in the discovery, development and commercialization of products for use in defense against biological warfare agents such as smallpox and arenaviruses. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, SIGA also gets F’s. For a full analysis of SIGA stock, visit Portfolio Grader.
The rating of Genomic Health, Inc. (GHDX) slips from a D to an F. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. In Earnings Growth, Earnings Revisions, Equity and Margin Growth the stock gets F’s. The stock price has fallen 10.7% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. To get an in-depth look at GHDX, get Portfolio Grader’s complete analysis of GHDX stock.
Amarin Corporation Plc Sponsored ADR’s (AMRN) rating weakens this week, dropping to an F versus last week’s D. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock also rates an F in Cash Flow. As of Feb. 18, 2014, 15.2% of outstanding Amarin Corporation Plc Sponsored ADR shares were held short. For more information, get Portfolio Grader’s complete analysis of AMRN stock.
This week, Trius Therapeutics, Inc. (TSRX) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For a full analysis of TSRX stock, visit Portfolio Grader.
This week, Discovery Laboratories, Inc.’s (DSCO) rating worsens to a D from the company’s C rating a week ago. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. Trade volume is up 439.6% from the previous week. To get an in-depth look at DSCO, get Portfolio Grader’s complete analysis of DSCO stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
